Aaron Edwards
Co-Founder & Chief Executive Officer KiraGen Bio
With a decade in cellular immunotherapy, Aaron has driven advancements in CAR-T and TCR-T therapies at bluebird bio, Beam Therapeutics (BEAM-201), Eli Lilly, and more. With a Harvard MS/MBA blending science and business, he leads KiraGen Bio’s mission to develop next-generation multiplex-edited cell therapies, overseeing strategy, fundraising, and partnerships.
